Literature DB >> 20430312

Headache.

Peter J Goadsby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20430312      PMCID： PMC5084094          DOI： 10.1016/j.nurt.2010.03.007

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  43 in total

1.  Nitric oxide synthase inhibition in migraine.

Authors:  L H Lassen; M Ashina; I Christiansen; V Ulrich; J Olesen
Journal:  Lancet       Date:  1997-02-08       Impact factor: 79.321

2.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.

Authors:  D J Goldstein; K I Roon; W W Offen; N M Ramadan; L A Phebus; K W Johnson; J M Schaus; M D Ferrari
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

Review 4.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Authors:  David Dodick; Richard B Lipton; Vincent Martin; Vasilios Papademetriou; Wayne Rosamond; Antoinette MaassenVanDenBrink; Hassan Loutfi; K Michael Welch; Peter J Goadsby; Steven Hahn; Susan Hutchinson; David Matchar; Stephen Silberstein; Timothy R Smith; R Allan Purdy; Jane Saiers
Journal:  Headache       Date:  2004-05       Impact factor: 5.887

5.  Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input.

Authors:  Thorsten Bartsch; Peter J Goadsby
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

6.  Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study.

Authors:  Brian Burns; Laurence Watkins; Peter J Goadsby
Journal:  Lancet Neurol       Date:  2008-10-07       Impact factor: 44.182

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

9.  Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial.

Authors:  M Ashina; L H Lassen; L Bendtsen; R Jensen; J Olesen
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input.

Authors:  P J Goadsby; J D Classey
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.